SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

China Approves Bayer’s Sevabertinib as First-Line Treatment for HER2-Mutated Lung Cancer

The approval expands sevabertinib’s approved use in China to first-line treatment for lung cancer with a HER2 mutation.

Related stories